| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa723e37dcc12799b720cea79afd668d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-327
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5031 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-327 |
| filingDate |
2015-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3bc2a691d7e552142cfac46c666d8f6 |
| publicationDate |
2021-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2855985-T3 |
| titleOfInvention |
Therapeutic agent for use in the treatment of infections |
| abstract |
Nanoscale or microscale therapeutic agent for use in treating human or animal infection comprising microparticle and / or nanoparticle carriers charged individually or in combination with one or more inert chemical precursors comprising a peroxygen donor and a acetyl donor, encapsulating the carriers to the chemical precursor or precursors that are activated in situ at the site of an infection by the physiological environment in such a way that the peroxygen donor forms hydrogen peroxide and the acetyl donor reacts with hydrogen peroxide to produce a mixture of peracetic acid and hydrogen peroxide, and characterized in that the particle carriers consist of a biodegradable polymer and have been prepared, and the chemical precursors incorporated into them, through a thermally induced phase separation and lyophilization process. |
| priorityDate |
2014-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |